Royalty Pharma Q2 GAAP net income attributable to company falls 44% to $18 million; non-GAAP adjusted EBITDA rises 16% to $736 million

• Royalty Pharma posted second-quarter results with net cash from operating activities more than doubling to $728 million.
• Portfolio Receipts rose 6% to $773 million, while Royalty Receipts climbed 14% to $768 million.
• Net income attributable to shareholders fell to $18 million, while GAAP operating income dropped 37% to $133 million.
• Non-GAAP adjusted EBITDA increased 16% to $736 million; capital deployment totaled $349 million.
• Raised 2026 Portfolio Receipts guidance to $3.4 billion-$3.5 billion; acquired a cliramitug royalty for up to $425 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royalty Pharma plc published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.